Ketorolac ophthalmic - Allergan

Drug Profile

Ketorolac ophthalmic - Allergan

Alternative Names: ACULAR; ACULAR LS; ACULAR PF; ACUVAIL; Ketorolac tromethamine

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Allergan
  • Class 2 ring heterocyclic compounds; Carboxylic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic conjunctivitis; Postoperative inflammation; Postoperative pain

Most Recent Events

  • 24 Jul 2009 Final efficacy data from two phase III trials of ACUVAIL™ in postoperative pain and inflammation following cataract surgery released by Allergan
  • 24 Jul 2009 The US FDA approves ACUVAIL™, a 45% ketorolac tromethamine ophthalmic solution, for the treatment of pain and inflammation following cataract surgery
  • 10 Jul 2004 Launched for Postoperative inflammation in Panama (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top